European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"IRMA: Machine learning-based harmonization of $$^{18}$$ F-FDG PET brain scans in multi-center studies","authors":"S.S. Lövdal, R. van Veen, G. Carli, R. J. Renken, T. Shiner, N. Bregman, R. Orad, D. Arnaldi, B. Orso, S. Morbelli, P. Mattioli, K. L. Leenders, R. Dierckx, S. K. Meles, M. Biehl","doi":"10.1007/s00259-025-07114-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07114-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Center-specific effects in PET brain scans arise due to differences in technical and procedural aspects. This restricts the merging of data between centers and introduces source-specific bias.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We demonstrate the use of the recently proposed machine learning method Iterated Relevance Matrix Analysis (IRMA) for harmonization of center-specific effects in brain <span>(^{18})</span>F-Fluorodeoxyglucose (<span>(^{18})</span>F-FDG) PET scans. The center difference is learned by applying IRMA on PCA-based feature vectors of healthy controls (HC), resulting in a subspace <span>(varvec{V})</span>, representing information not comparable between centers, and the remaining subspace <span>(varvec{U})</span>, where no center differences are present. In this proof-of-concept study, we demonstrate the properties of the method using data from four centers. After center-harmonization, a Generalized Matrix Learning Vector Quantization (GMLVQ) model was trained to discriminate between Parkinson’s disease, Alzheimer’s disease and Dementia with Lewy Bodies.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>At the initial IRMA iteration, the system was able to determine the center origin of the four HC cohorts almost perfectly. The method required six iterations, corresponding to a six-dimensional subspace <span>(varvec{V})</span>, to determine the entire center difference. An uncorrected disease classification model was highly biased to center-specific effects, creating a falsely inflated performance when applying internal (cross-) validation. The cross-validation performance of the center-harmonized model remained high, while it generalized significantly better to unseen test cohorts. Furthermore, the framework is highly transparent, providing analytic reconstructions of the correction and visualizations of the data in voxel space.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>IRMA can be used to learn and disregard center-specific information in features extracted from brain <span>(^{18})</span>F-FDG PET scans, while retaining disease-specific information.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"25 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated quantification of brain PET in PET/CT using deep learning-based CT-to-MR translation: a feasibility study","authors":"Daesung Kim, Kyobin Choo, Sangwon Lee, Seongjin Kang, Mijin Yun, Jaewon Yang","doi":"10.1007/s00259-025-07132-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07132-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Quantitative analysis of PET images in brain PET/CT relies on MRI-derived regions of interest (ROIs). However, the pairs of PET/CT and MR images are not always available, and their alignment is challenging if their acquisition times differ considerably. To address these problems, this study proposes a deep learning framework for translating CT of PET/CT to synthetic MR images (MR_SYN) and performing automated quantitative regional analysis using MR_SYN-derived segmentation.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>In this retrospective study, 139 subjects who underwent brain [¹⁸F]FBB PET/CT and T1-weighted MRI were included. A U-Net-like model was trained to translate CT images to MR_SYN; subsequently, a separate model was trained to segment MR_SYN into 95 regions. Regional and composite standardised uptake value ratio (SUVr) was calculated in [¹⁸F]FBB PET images using the acquired ROIs. For evaluation of MR_SYN, quantitative measurements including structural similarity index measure (SSIM) were employed, while for MR_SYN-based segmentation evaluation, Dice similarity coefficient (DSC) was calculated. Wilcoxon signed-rank test was performed for SUVrs computed using MR_SYN and ground-truth MR (MR_GT).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Compared to MR_GT, the mean SSIM of MR_SYN was 0.974 ± 0.005. The MR_SYN-based segmentation achieved a mean DSC of 0.733 across 95 regions. No statistical significance (<i>P</i> &gt; 0.05) was found for SUVr between the ROIs from MR_SYN and those from MR_GT, excluding the precuneus.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>We demonstrated a deep learning framework for automated regional brain analysis in PET/CT with MR_SYN. Our proposed framework can benefit patients who have difficulties in performing an MRI scan.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"24 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on Terbium-149: advancing preclinical research in targeted alpha therapy.","authors":"Serkan Kuyumcu, Yasemin Şanlı","doi":"10.1007/s00259-025-07151-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07151-z","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning-based time-of-flight (ToF) enhancement of non-ToF PET scans for different radiotracers","authors":"Abolfazl Mehranian, Scott D. Wollenweber, Kevin M. Bradley, Patrick A. Fielding, Martin Huellner, Andrei Iagaru, Meghi Dedja, Theodore Colwell, Fotis Kotasidis, Robert Johnsen, Floris P. Jansen, Daniel R. McGowan","doi":"10.1007/s00259-025-07119-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07119-z","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Aim</h3><p>To evaluate a deep learning-based time-of-flight (DLToF) model trained to enhance the image quality of non-ToF PET images for different tracers, reconstructed using BSREM algorithm, towards ToF images.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A 3D residual U-NET model was trained using 8 different tracers (FDG: 75% and non-FDG: 25%) from 11 sites from US, Europe and Asia. A total of 309 training and 33 validation datasets scanned on GE Discovery MI (DMI) ToF scanners were used for development of DLToF models of three strengths: low (L), medium (M) and high (H). The training and validation pairs consisted of target ToF and input non-ToF BSREM reconstructions using site-preferred regularisation parameters (beta values). The contrast and noise properties of each model were defined by adjusting the beta value of target ToF images. A total of 60 DMI datasets, consisting of a set of 4 tracers (¹⁸F-FDG, ¹⁸F-PSMA, ⁶⁸Ga-PSMA, ⁶⁸Ga-DOTATATE) and 15 exams each, were collected for testing and quantitative analysis of the models based on standardized uptake value (SUV) in regions of interest (ROI) placed in lesions, lungs and liver. Each dataset includes 5 image series: ToF and non-ToF BSREM and three DLToF images. The image series (300 in total) were blind scored on a 5-point Likert score by 4 readers based on lesion detectability, diagnostic confidence, and image noise/quality.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>In lesion SUV_max quantification with respect to ToF BSREM, DLToF-H achieved the best results among the three models by reducing the non-ToF BSREM errors from -39% to -6% for ¹⁸F-FDG (38 lesions); from -42% to -7% for ¹⁸F-PSMA (35 lesions); from -34% to -4% for ⁶⁸Ga-PSMA (23 lesions) and from -34% to -12% for ⁶⁸Ga-DOTATATE (32 lesions). Quantification results in liver and lung also showed ToF-like performance of DLToF models. Clinical reader resulted showed that DLToF-H results in an improved lesion detectability on average for all four radiotracers whereas DLToF-L achieved the highest scores for image quality (noise level). The results of DLToF-M however showed that this model results in the best trade-off between lesion detection and noise level and hence achieved the highest score for diagnostic confidence on average for all radiotracers.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This study demonstrated that the DLToF models are suitable for both FDG and non-FDG tracers and could be utilized for digital BGO PET/CT scanners to provide an image quality and lesion detectability comparable and close to ToF.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"35 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathological and radiological features of false-positive lesions on [68Ga]Ga-PSMA-11 PET/CT in primary staging of prostate cancer: a radio-pathology matching analysis","authors":"Renjie Li, Yao Fu, Shan Peng, Fengjiao Yang, Shuyue Ai, Feng Wang, Shun Zhang, Hongqian Guo, Xuefeng Qiu","doi":"10.1007/s00259-025-07148-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07148-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>The aim of this study was to investigate the radiological and pathological characteristics of false-positive lesions on [⁶⁸Ga]Ga-PSMA-11 PET/CT during the primary staging of prostate cancer.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This study retrospectively analyzed 216 prostate cancer patients who had [⁶⁸Ga]Ga-PSMA-11 PET/CT before radical prostatectomy. False-positive lesion was defined as suspicious lesion with PRIMARY score ≥ 3 on PET/CT but benign on whole-mount pathology. To analyze the radiological and pathological features of false-positive lesions, no-uptake areas on PSMA PET/CT with benign pathology on the whole-mount specimen were randomly delineated and defined as true-negative lesions. The pathological features of false-positive and true-negative lesions were compared using Fisher’s exact test. The differences of SUVmax and SUVmean between false-positive and true-positive lesions were determined and compared using the Wilcoxon matched-pairs signed-ranks test. In addition, PSMA expression in false-positive lesions was assessed by immunohistochemistry.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 36 false-positive lesions were identified on [⁶⁸Ga]Ga-PSMA-11 PET/CT: 25 (69.44%) were simple atrophy with cyst formation, 7 (19.44%) were prostatic nodular hyperplasia, 3 (8.33%) were inflammation and 1 (2.78%) was normal glands. A comparable number of 36 true-negative lesions were delineated: 21 (58.33%) were normal glands, 8 (22.22%) were simple atrophy with cyst formation, 6 (16.67%) were prostatic nodular hyperplasia, and 1 (2.78%) were inflammation. The Fisher’s exact test revealed a statistically significant difference in the prevalence of simple atrophy with cyst formation between false-positive and true-negative lesions (69.44% vs. 22.22%; <i>P</i> &lt; 0.001). Differences in SUVmax and SUVmean between false-positive and true-positive lesions were also statistically significant (both <i>P</i> &lt; 0.001). PSMA expression in false-positive lesions was confirmed via immunohistochemistry.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This study determined that simple atrophy with cyst formation is a distinctive pathological feature of false-positive lesions on [⁶⁸Ga]Ga-PSMA-11 PET/CT. This observation is likely attributable to the elevated PSMA expression in simple atrophy with cyst formation, as confirmed by histological analysis. Additionally, false-positive lesions were found to have significantly lower SUV compared to true-positive lesions.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"1 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143427332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The untapped potential of dosomics for theranostics: shaping the future of personalized medicine","authors":"Luca Filippi, Orazio Schillaci, Laura Evangelista","doi":"10.1007/s00259-025-07161-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07161-x","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"129 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging","authors":"Huanhuan Liu, Xiaojun Zhang, Jingfeng Zhang, Yue Pan, Hui Wen, Xiaodan Xu, Shina Wu, Yuan Wang, Cong Zhang, Guangyu Ma, Yachao Liu, Ruimin Wang, Jinming Zhang","doi":"10.1007/s00259-025-07131-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07131-3","url":null,"abstract":"&lt;h3 data-test=\"abstract-sub-heading\"&gt;Objective&lt;/h3&gt;&lt;p&gt;This study aims to investigate the efficacy and safety of prostate-specific membrane antigen (PSMA) radiolabeled with copper-64 (&lt;sup&gt;64&lt;/sup&gt;Cu) using the bifunctional chelating agents (BFCAs) NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). As widely utilized BFCAs in the development of radiopharmaceuticals, NOTA and DOTA play a critical role in ensuring stable chelation with &lt;sup&gt;64&lt;/sup&gt;Cu. This study evaluates the stability, bioavailability, and therapeutic potential of these radiolabeled compounds in preclinical models and initial clinical trials.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Methods&lt;/h3&gt;&lt;p&gt;&lt;sup&gt;64&lt;/sup&gt;Cu-DOTA-PSMA-3Q and &lt;sup&gt;64&lt;/sup&gt;Cu-NOTA-PSMA-3Q were synthesized by manual labeling. The radiochemical purity, stability, specificity and biological distribution of the product were evaluated by preclinical studies. In 23 patients with suspected prostate cancer, PET/CT imaging was used to evaluate the potential and differences in biological distribution of &lt;sup&gt;64&lt;/sup&gt;Cu-DOTA-PSMA-3Q and &lt;sup&gt;64&lt;/sup&gt;Cu-NOTA-PSMA-3Q in clinical diagnosis.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Results&lt;/h3&gt;&lt;p&gt;The radiochemical purities of &lt;sup&gt;64&lt;/sup&gt;Cu-DOTA-PSMA-3Q and &lt;sup&gt;64&lt;/sup&gt;Cu-NOTA-PSMA-3Q are more than 98% and have good stability in vitro. Biodistribution studies in healthy mice revealed that both tracers primarily underwent renal excretion post-injection. Liver uptake of &lt;sup&gt;64&lt;/sup&gt;Cu-DOTA-PSMA-3Q was significantly higher than that of &lt;sup&gt;64&lt;/sup&gt;Cu-NOTA-PSMA-3Q at 1 h after injection (&lt;i&gt;P&lt;/i&gt;&lt;0.05). Micro-PET/CT imaging in 22Rv1 tumor-bearing mice demonstrated similar tumor uptake for both tracers at 1 h after injection (&lt;i&gt;P&lt;/i&gt;&gt;0.05). However, after 24 h, &lt;sup&gt;64&lt;/sup&gt;Cu-DOTA-PSMA-3Q exhibited significantly better tumor retention compared to &lt;sup&gt;64&lt;/sup&gt;Cu-NOTA-PSMA-3Q (&lt;i&gt;P&lt;/i&gt;&lt;0.05). In clinical PET/CT imaging involving 23 patients with suspected prostate cancer, no adverse reactions or significant changes in vital signs were observed, underscoring the safety of both tracers. Notably, &lt;sup&gt;64&lt;/sup&gt;Cu-NOTA-PSMA-3Q demonstrated higher uptake in the lacrimal glands (17.73 vs. 10.84), parotid glands (20.98 vs. 16.30), and submandibular glands (20.26 vs. 17.28) compared to &lt;sup&gt;64&lt;/sup&gt;Cu-DOTA-PSMA-3Q. Conversely, uptake in the sublingual glands was lower for &lt;sup&gt;64&lt;/sup&gt;Cu-NOTA-PSMA-3Q (7.10 vs. 7.49). Of particular clinical relevance, liver uptake of &lt;sup&gt;64&lt;/sup&gt;Cu-NOTA-PSMA-3Q was significantly lower than that of &lt;sup&gt;64&lt;/sup&gt;Cu-DOTA-PSMA-3Q (4.04 vs. 8.18), highlighting a key difference in their biodistribution profiles.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Conclusions&lt;/h3&gt;&lt;p&gt;Both NOTA and DOTA are suitable chelators for the development of &lt;sup&gt;64&lt;/sup&gt;Cu-labeled PSMA-3Q tracers for PET/CT imaging. DOTA showed better tumor retention 24 h after injection, while NOTA showed lower uptake in","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"79 6 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143417381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Striatal dopamine transporter uptake predicts neuronal hypometabolism and visuospatial function in Parkinson's disease.","authors":"Seungbeom Seo, Yeo Jun Yoon, Sangwon Lee, Hyunkeong Lim, Kyobin Choo, Daesung Kim, Hyunkyung Han, Seongjin Kang, Jaekyung Park, Phil Hyu Lee, Dongwoo Kim, Mijin Yun","doi":"10.1007/s00259-025-07137-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07137-x","url":null,"abstract":"<p><strong>Purpose: </strong>While many studies have explored the link between biomarkers and cognitive decline in Parkinson's disease (PD), a more comprehensive approach is needed, combining striatal dopamine depletion, cerebral glucose metabolism, and cognitive assessments. In this study, we investigated the relationships between striatal dopamine transporter (DAT) uptake, cerebral glucose hypometabolism, and cognition, as well as the potential progression pattern of these changes in PD.</p><p><strong>Methods: </strong>We enrolled 62 patients with PD and 33 healthy controls. The subjects underwent N-(3-[¹⁸F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) PET/CT, [¹⁸F] fluorodeoxyglucose (FDG) PET/CT, and detailed neuropsychological testing. The mean standard uptake value ratio (SUVR) value of the regions showing significantly lower metabolism in PD patients was defined as SUVR_[hypo]. The relationship between striatal DAT uptake and SUVR_[hypo] was assessed using general linear models, while their impact on cognitive function was evaluated with multivariate linear regression. Additionally, the pattern of their changes was assessed using an event-based model.</p><p><strong>Results: </strong>Compared to the control group, PD patients exhibited glucose hypometabolism in specific cortical regions. DAT uptake in the anterior and posterior putamen was positively correlated with SUVR_[hypo]. Decreased DAT uptake in the anterior putamen and caudate nucleus was associated with lower z-score in visuospatial function. Decreased DAT uptake in the posterior and anterior putamen occurred first, followed by PD-related cerebral hypometabolism, and visuospatial function.</p><p><strong>Conclusion: </strong>This study highlights the interconnectedness of dopaminergic depletion, cerebral glucose hypometabolism, and visuospatial dysfunction, proposing that striatal DAT uptake may serve as an early biomarker for cerebral hypometabolism and cognitive impairment in PD.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings.","authors":"Sijuan Zou, Zheng Liu, Jianyuan Zhou, Shuang Song, Dongdong Wang, Dongling Zhu, Siyuan Cheng, Zhaoting Cheng, Yuankai Zhu, Tianci Yu, Donghui Pan, Min Yang, Xiaohua Zhu","doi":"10.1007/s00259-025-07142-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07142-0","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Recently, novel human epidermal growth factor receptor 2 antibody-drug conjugate therapies have shown remarkable efficacy in treating urothelial carcinoma, highlighting the growing need for comprehensive assessment of HER2 expression in tumors to identify patients who could benefit. However, non-invasive methods for assessing HER2 status in patients with urothelial carcinoma remain limited. This study aimed to preliminarily evaluate the clinical potential of [68Ga]Ga-HER2 affibody PET/CT for non-invasive assessment of HER2 expression in patients with urothelial carcinoma.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;A cohort of 25 patients with urothelial carcinoma was retrospectively included from a prospective parent study (NCT05535621), and sequential PET/CT using [68Ga]Ga-HER2 affibody and [18 F] FDG was performed. HER2 status was assessed through pathological evaluation using immunohistochemistry, with scoring categories of 0, 1+, 2+, and 3+. Lesion uptake on PET/CT was quantified using the maximum standardized uptake value (SUVmax). Comparisons of SUVmax between primary tumor groups with different HER2 expression levels (HER2-positive IHC 2+, 3 + vs. HER2-negative IHC 0, 1+, and HER2-expression IHC 1+, 2+, 3 + vs. HER2-zero IHC 0) were conducted using nonparametric statistical tests. Additionally, the correlation between tumor SUVmax and HER2 expression status was analyzed, and the HER2 PET metastasis-positive rate at the patient level in metastatic urothelial carcinoma was determined.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Twenty-five patients (mean age, 65.6 years ± 11.1 [SD]); 18 men) with urothelial carcinoma were enrolled. HER2 status in primary tumor was confirmed IHC 0 in four cases, IHC 1 + in three cases, IHC 2 + in six cases, IHC 3 + in three cases, and unknown in seven cases with potential HER2 expression. One patient with ureterostomy recurrence had HER2 IHC 1+, while another case was confirmed IHC 2 + through biopsy of metastatic lesion. In 16 participants with urothelial carcinoma, the SUVmax of HER2-positive primary tumors (IHC 2 + and 3+, n = 9) were higher than those of HER2-negative tumors (IHC 0 and 1+, n = 7) (median SUVmax, 7.07 ± 0.69 vs. 4.48 ± 1.14, p = 0.042) on [68Ga]Ga-HER2 affibody PET/CT. Additionally, a similar difference was observed between the HER2-expression group (IHC 1+, 2+, 3+, n = 12) and the HER2-zero group (IHC 0, n = 4) (median SUVmax, 6.97 ± 0.70 vs. 2.85 ± 0.19, p = 0.001). Primary tumors in 13 of the 16 patients were semi-quantitatively measurable on FDG PET/CT imaging, with no significant difference in FDG SUVmax between the HER2-positive and HER2-negative group (7 HER2-positive vs. 6 HER2-negative; median SUVmax: 19.56 ± 5.02 vs. 19.10 ± 3.13, p = 0.731). Spearman correlation analysis revealed a positive correlation between HER2 PET SUVmax and HER2 expression levels in primary urothelial carcinoma (R = 0.727, p = 0.001), whereas no correlation was found between FDG SUVmax ","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of subclinical microcalcification and inflammation with carotid atheroma development: a dual-tracer PET/CT study","authors":"Shiv Patil, Rithvik Kata, Eric Teichner, Robert Subtirelu, Mohanad Ghonim, Mohamed Ghonim, Omar Al-Daoud, Miraziz Ismoilov, Lancelot Herpin, Cyrus Ayubcha, Thomas Werner, Poul Flemming Høilund-Carlsen, Abass Alavi","doi":"10.1007/s00259-025-07127-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07127-z","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Carotid artery atherosclerosis, a significant manifestation of cardiovascular disease (CVD) and leading cause of stroke, develops through a gradual process of arterial inflammation and calcification. This study explores the relationship between arterial inflammation (18 F-FDG PET/CT) and vascular calcification (18 F-NaF PET/CT) in the left and right common carotid arteries (LCC/RCC) and their association with CVD and thromboembolic risk in patients with subclinical atherosclerosis.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A cohort of 115 subjects (73 healthy volunteers, 42 at-risk for CVD) underwent 18 F-NaF and 18 F-FDG PET/CT imaging. Radiotracer uptake was quantitatively assessed by measuring the average blood-pool-corrected mean standardized uptake value (aSUVmean).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Relative to healthy volunteers, at-risk subjects had greater uptake of NaF and FDG (10–22% and 16–27% higher, respectively, in both arteries, <i>p</i> &lt; 0.05). On multivariate regression, NaF aSUVmean correlated with age and BMI (<i>p</i> &lt; 0.01), and FDG aSUVmean correlated with BMI (<i>p</i> ≤ 0.01), fibrinogen (<i>p</i> &lt; 0.01 in LCC only), and total cholesterol (<i>p</i> = 0.02 in RCC only). NaF aSUVmean increased with elevated 10-year CVD risk (<i>p</i> = 0.003 in LCC only), while no significant trend was seen for FDG. NaF and FDG aSUVmean increased with elevated thromboembolic risk in both arteries (<i>p</i> &lt; 0.05). No correlations between NaF and FDG aSUVmean were observed (<i>p</i> &gt; 0.05).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>18 F-NaF PET/CT may serve as a prognostic tool for carotid microcalcification and subclinical atherosclerosis, while the utility of 18 F-FDG PET/CT remains uncertain.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial registration</h3><p>“Cardiovascular Molecular Calcification Assessed by 18F-NaF PET CT (CAMONA)”, NCT01724749, https://clinicaltrials.gov/study/NCT01724749.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"63 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}